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The literature contains numerous references describing heterogeneity for tumor phenotypes including cell proliferation, invasiveness, metastatic potential, and response to therapies. However, data regarding angiogenic heterogeneity are limited. In this study, we investigated the degree of intertumoral angiogenic heterogeneity present in head and neck squamous cell carcinomas (HNSCC). In addition, we investigated the biological relevance that this heterogeneity may have in the context of cytokine directed antiangiogenic therapy. Keratinocytes were harvested from HNSCC specimens using laser capture microdissection (LCM). Gene expression profiling of the RNA extracted from these specimens demonstrated variability in the expression of angiogenesis-related genes. Hierarchical clustering and principal component analyses (PCA) demonstrated the presence of unique patient clusters, suggesting that there may be two potentially distinct pathways by which HNSCC induce angiogenesis. Immunohistochemistry for VEGF, IL-8/CXCL8, HGF, and FGF-2, cytokines that play functional roles in HNSCC angiogenesis was performed on the original patient samples as well as a larger panel of normal, dysplastic and HNSCC specimens to validate the heterogeneous expression observed in the gene expression profiling studies. Finally, the therapeutic response of HNSCC tumor xenografts to anti-VEGF therapy was found to be dependent on the amount of VEGF produced by the tumor cells. These findings support the hypothesis of intertumoral angiogenic heterogeneity. They imply that there are differences with regard to the specific molecular mechanisms by which individual tumors within the same histological type induce angiogenesis. Moreover, they demonstrate the need for a more in-depth understanding of the variability of the angiogenic phenotype within a given type of neoplasm when designing cytokine targeted antiangiogenic therapies. Finally, they suggest that studies in conjunction with the ongoing clinical trials that explore the correlation between target expression and clinical outcome are warranted. KEYWORDS: angiogenesis; cancer; oral; heterogeneity; therapy It has been largely assumed that tumors of a given histological type induce angiogenesis by the same specific molecular mechanism(s). Such a concept is intellectually satisfying for a number of reasons. First, it implies that observations about a given mechanism or angiogenic factor made in one cell line/tumor will be applicable to all cell lines/ tumors of that histological type. Secondly, it suggests that therapies designed to combat a specific mechanism of tumor angiogenesis will be effective on other tumors of that type. While such concepts neatly compartmentalize angiogenesis, they are not consistent with other tumor phenotypes. Heterogeneity of tumor phenotypes including cell proliferation, invasiveness, metastatic potential, and response to therapies is a well-established principle in cancer biology. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] This prompted us to ask if there was evidence for angiogenic heterogeneity in head and neck squamous cell carcinomas (HNSCC) as well. While limited, there are data that support the concept of intertumoral angiogenic heterogeneity in HNSCC. VEGF expression has been reported to be elevated in both oral dysplasia and HNSCC. [12] [13] [14] [15] [16] However, there are also data suggesting that there is interlesional angiogenic variation in HNSCC. For example, using in situ hybridization, Denhart et al either VEGF or its receptors. This implies that 50% of the premalignant and 25% of the malignant lesions in this study were inducing angiogenesis by an alternative mechanism that did not seem to involve VEGF. In addition, Tae et al 17 found that levels of VEGF in premalignant and malignant oral tissue were lower than in normal tissue. However, they did not investigate the expression of other angiogenic factors that might be important. Using an unbiased approach to test the hypothesis of intertumoral angiogenic heterogeneity, we sought to determine the global expression profile of angiogenic factors in HNSCC using gene-expression profiling to characterize in detail the neoplasm's angiogenic phenotype. Our hypothesis was that, like other tumor phenotypes, the mechanism of how and the degree to which individual neoplasms of the same histological type induce blood vessel growth is variable. Here, we report that there is a considerable amount of intertumoral heterogeneity with regard to the angiogenic factors produced by human HNSCC. In addition, we demonstrate the presence of two major angiogenesis-related clusters of samples, identifying two potentially distinct pathways by which HNSCC induce blood vessel growth. These findings may have profound implications on how we study, diagnose, and ultimately design antiangiogenic therapies for HNSCC as well as other malignancies.
MATERIAL AND METHODS Cell Lines and Strains
The human HNSCC cell lines SCC-4, SCC-9, and SCC-25 were purchased from the ATCC (Manassas, VA, USA). These cells were grown in DMEM/Ham's F-12 (1:1) supplemented with 10% fetal bovine serum (FBS), hydrocortisone (0.4 mg/ ml), penicillin (100 U/ml), and streptomycin (50 mg/ml). The human OSCC-3 HNSCC cell line was established as previously described, 18 and grown in DMEM supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (50 mg/ml). Human HNSCC cell lines JSQ-3, SQ20B, SCC-28, SCC-58, and SCC-61 (kindly provided by Ralph Weichselbaum) were grown in DMEM/Ham's F-12 (1:1) with 20% FBS, hydrocortisone (0.4 mg/ml), penicillin (100 U/ml), and streptomycin (50 mg/ml).
The UM SCC-17B HNSCC cell line (kindly provided by Jacques Nor) was grown in DMEM supplemented with 10% FBS, L-glutamine, penicillin, and streptomycin. All tissue culture reagents were purchased from Invitrogen (Carlsbad, CA, USA). Normal human keratinocytes were purchased from Cambrex, (San Diego, CA, USA) and cultured in KGM-2. All keratinocytes were cultured at 371C in a 5% CO2-95% air environment in humidified incubators.
Tissue Samples, Laser Capture Microdissection and RNA Extraction Primary HNSCC samples were obtained with informed consent from patients undergoing surgery. All samples were immediately embedded in TissueTek OCT medium (Fisher Scientific, Pittsburgh, PA, USA) and frozen at À801C. Frozen sections were cut at 5-8 mm thicknesses and laser capture microdissection (LCM) was performed using the Arcturus PixCell II System (Arcturus, Mountain View, CA, USA). To ensure a representative collection of tumor cells from each neoplasm, nests of tumor cells were harvested from multiple regions including the leading center of the tumor as well as the invasive front. Approximately 10 000 cells from a total of 6-10 slides were collected from each tumor sample. Total RNA was extracted from captured cells with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), treated with DNAse to remove genomic DNA with DNA-Free (Ambion, Austin, TX, USA), and stored at À801C.
RNA Amplification
Approximately one-third of the total RNA collected by LCM was amplified following the high fidelity amplification protocol as described previously. 19 One round of amplification was performed to yield enough amplified RNA for microarray hybridization.
Labeling, Hybridization, and Scanning of Microarray
The labeling and hybridization procedures were conducted as specified by the manufacturer of the microarray filters (Research Genetics/Invitrogen). cDNA probes were made from 500 ng of amplified RNA with [ 33 P]-dATP (Amersham Biosciences, Piscataway, NJ, USA) by oligo-dT-primed polymerization using SuperScript II Reverse Transcriptase (Invitrogen). ResGent GeneFilters microarray GF211 (Human 'Named Genes' GeneFilters Microarrays) from Research Genetics was used. The microarray filters were hybridized with denatured probe overnight, washed, and exposed to phosphorimager screens. The images were scanned by a Molecular Dynamics Storm Imager (Packard, Meriden, CT, USA) at 600 dpi resolution, and the raw intensity signal data were generated with Pathways II Software.
Data Analysis
Raw image files were converted into numerical values using Pathways II software (Research Genetics). Pre-processing of the raw expression data, which included normalization and filtering, was performed on all samples before any data analysis. This standardization was based on the intensity of internal control spots and genes with low overall variance across all of the samples were removed since they were of limited interest. The Kruskal-Wallis test, a non-parametric method, was used to determine those genes that were differentially expressed across the three groups, and the Wilcoxon rank-sum test was used for pairwise comparisons.
Hierarchical clustering was performed using Cluster software on standardized data and expression maps of clustered genes were created using TreeView (both available at http:// rana.lbl.gov/EisenSoftware.htm). Clusters were created using the algorithm of Eisen and co-workers. This algorithm sorts through all the data to find pairs of genes that behave most similarly in each experiment and then progressively adds other genes to the initial pairs to form clusters of potentially similar behavior. In the expression maps, each square represents the expression level of a single transcript in a single sample; red and green, transcript levels above and below, respectively, the median for that gene across all of the samples. Color saturation is proportional to the magnitude of the difference from the mean.
For the principal component analysis (PCA) of the samples, the average background was subtracted from the raw intensity value for each gene. The total mean expression values were calculated for each microarray. The array with a mean expression value closest to the average of all 13 mean expression values was chosen as the reference array. The microarrays were normalized by fitting a linear regression between the expression values for each microarray and the expression values for the reference microarray and dividing by the value of each regression coefficient for that microarray. Either the entire gene list or the 114 angiogenesis-related genes on the microarray were selected, and the filtered data matrix was mean-centered and scaled and PCA performed using Matlab (Mathworks, Natick, MA, USA).
Immunohistochemistry on Human Tumor Samples
For the original snap-frozen biopsy samples, tissues were sectioned at 5 mm thicknesses and fixed in cold acetone. Endogenous peroxidase activity was quenched in 3% hydrogen peroxide and proteins were blocked with 1% BSA/ Tris-PBS. Rabbit polyclonal antibodies for VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and IL-8/CXCL8 (Endogen, Woburn, MA, USA) were used at 1:75 and 1:50 dilutions, respectively. Antibody binding was visualized with anti-rabbit polymer labeled HRP bound secondary reagent (EnVision þ , DAKO, Carpinteria, CA, USA), developed with DAB chromogen and counterstained with hematoxylin. For CD31 detection, the primary antibody PECAM (Santa Cruz Biotechnology) was applied at 1:100 dilution. Antibody binding was visualized using the LSAB Kit (DAKO) and counterstained with hematoxylin. Corresponding negative control experiments were performed by omitting the incubation step with the primary antibody. For the archival samples, formalin-fixed paraffin-embedded tissue microarrays (TMAs), immunohistochemistry was performed following the manufacturer's instructions with minor modifications. For the detection of VEGF and IL-8/CXCL8, deparaffinized sections were microwaved in citrate buffer, and primary antibody applied for 1 h at room temperature at dilutions of 1:100 and 1:50, respectively. For the detection of FGF-2 and HGF, deparaffinized slides were placed in a decloaking chamber using ET buffer, and primary antibody applied for 1 h at room temperature at a dilutions of 1:100 and 1:50, respectively. Antibody binding was visualized using the rabbit EnVision þ kit (DAKO). Corresponding negative control experiments were performed by omitting incubation with primary antibody. The primary antibodies VEGF (catalog no. sc-15), IL-8/CXCL8 (catalog no. sc-7922), FGF-2 (catalog no. sc-79), and HGF (catalog no. sc-7949) were purchased from Santa Cruz Biotechnology.
Immunohistochemistry for Mouse Tumor Xenografts CD31 detection was achieved using the primary antibody (Santa Cruz Biotechnology; catalog no. sc-1506). Retrieval was performed on the deparaffinized sections using citrate buffer in a microwave. The antibody was applied at a 1:200 dilution in PBS for 1 h at room temperature. The biotinylated secondary antibody (Dako Labeled Streptavidin-Biotin kit; catalog no. Â 0590) was applied for 30 min, followed by incubations with Vectastain Elite ABC Reagents (Vector Laboratories, Burlingame, CA, USA; catalog no. PK-6105). For determination of cell proliferation, sections were treated in citrate buffer using a decloaking chamber, incubating at a 1:1 dilution using PCNA antibody (Zymed, San Francisco, CA, USA; catalog no. 93-1143) for 1 h followed by streptavidin-peroxidase. Apoptotic cells were detected using an antibody to cleaved caspase-3 (Biocare Medical, Walnut Creek, CA, USA; catalog no. CP229A). The detection of caspase-3 was achieved by using deparaffinized sections in a decloaking chamber with citrate buffer, and primary antibody applied for 1 h at room temperature at a dilution of 1:25. Antibody binding was visualized with anti-rabbit polymer labeled HRP bound secondary reagent (EnVision þ , DAKO). All three immunohistochemistry stains were developed with DAB chromogen and counterstained with hematoxylin.
Scoring of Immunohistochemistry
A combined scoring method that accounts for the intensity of staining as well as the percentage of cells stained was employed for the evaluation of VEGF, IL-8/CXCL8, HGF, and FGF-2 as described previously. 20 Strong, moderate, weak, and negative staining intensities were scored as 3, 2, 1, and 0, respectively. For each of the intensity scores, the percentage of cells that stained at that level was estimated visually. The resulting combined score consisted of the sum of the percentage of stained cells multiplied by the intensity scores. For example, a case with 10% weak staining, 10% moderate staining, and 80% strong staining would be assigned a score of 270 (10 Â 1 þ 10 Â 2 þ 80 Â 3 ¼ 270) out of a possible score of 300.
The determination of microvessel density (MVD) using CD31 as a marker was performed as described previously. [21] [22] [23] [24] Briefly, using low power magnification, the region containing the most intense area of tumor neovascularization was chosen for counting in each of the tumors. For the normal control tissue, MVD was determined by finding the most intense area of neovascularization directly below the overlying mucosa. Individual microvessels were counted using a Â 100 field ( Â 10 objective lens and Â 10 ocular lens). Any brown staining endothelial cells that were clearly separate in appearance were counted as individual vessels. Ten random fields within this hotspot area were viewed and counted at Â 100. Results were expressed as the total number of microvessels observed in the 'hot spot' region of each individual tumor. The proliferating and apoptotic cells were counted at high power ( Â 400) and expressed as a percentage of the total number of cells.
Generation of Conditioned Media and VEGF ELISA Assay
Conditioned media (CM) was generated from normal keratinocytes and HNSCC cell lines by rinsing cells with DMEM three times and then incubating the cells in DMEM/ F-12 or DMEM with 1% FBS for 24 h. The media were collected and centrifuged, and the supernatant was stored at À801C until use. Protein concentrations were determined using the Coomassie Protein Assay Reagent 23200 (Pierce Biomedical Company, St Louis, MO, USA). The levels of VEGF present in the CM from each sample were determined in duplicate using the Quantikine Immunoassay kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Concentration of VEGF expression was interpolated from a standard curve derived from assaying recombinant VEGF. Each sample was tested in two separate experiments. The average of the two assays is presented. Individual assays of the same sample varied from one another by less than 10%.
In Vivo Antiangiogenic Therapy Eight-week-old athymic nude mice were injected subcutaneously with 5 Â 10 6 cells (OSCC-3 and SQ-20B) in the right hind leg. Prior to the initiation of anti-VEGF therapy, tumors were allowed to grow to an average volume of approximately 200 mm 3 after which the mice were divided into three experimental groups (n ¼ 10 animals per treatment group) and treatment started. Group 1 was treated with 100 mg anti-human VEGF antibody (R&D Systems), group 2 with a nonspecific human IgG control antibody (Sigma, St Louis, MO, USA) and group 3 with PBS. Treatments were administered intraperitoneally on days 0, 3, 6, and 9, and tumor volumes were measured until day 12 following protocols previously published. 25 Statistical Analysis For the in vivo tumor studies, the data were analyzed using a repeated measures analysis of variance (ANOVA) with a Greenhouse-Geisser adjustment.
RESULTS

Distinct Angiogenic Subtypes in HNSCC
To characterize the global expression profile of angiogenic factors in HNSCC, malignant keratinocytes from 13 HNSCC specimens were harvested using LCM. The basic demographics for these patients are listed in Table 1 . Total RNA was then extracted, labeled, and used to probe nylon cDNA microarray filters that contained a total of approximately 4000 genes. The analysis of the resultant data was based on an analysis of the entire gene set as well as a subset of 114 angiogenesis-related genes that were present on the filters (see Supplementary Tables 1 and 2) .
Supervised hierarchical clustering using the 114-gene angiogenesis set was used to group the tumor expression profiles to one another on the basis of their overall similarity, resulting in the segregation of the patients into two major groups (Figure 1) . A number of important secreted angiogenic factors segregated with each of the two clusters. For example, tumors in cluster A tended to express higher levels of VEGF and FGF-2 and relatively low levels of IL-8/CXCL8 and HGF. Conversely, tumors within cluster B tended to express low levels of VEGF and FGF-2, and higher levels of IL-8/CXCL8 and HGF.
Using the same entire gene set and the 114 angiogenesisrelated gene set, the tumors were then reclustered by PCA, which reduces the dimensionality of complex data and displays the structure of the data on a reduced space. The dimensional reduction is obtained through linear transformations of the original data into orthogonal 'components'. The PCA clustering of the 13 HNSCC samples using the angiogenesis gene list revealed the presence of two major clusters of patient samples along with a third distinct, solitary sample (Figure 2a) . PCA analysis was also performed on the entire data set to determine if the angiogenesis-related genes represented a potentially key program for distinguishing between tumors. Contrary to the angiogenesis PCA analysis, the PCA clustering of the entire gene set demonstrated considerably less distinct clustering (Figure 2b ). This result led to the hypothesis that the two unique clusters of tumors Figure 1 TreeView map of differentially expressed genes of LCM harvested HNSCC cells. cDNA from 13 HNSCC samples were hydridized to nylon microarray filters containing 9184 genes. The data were then analyzed using the Kruskal-Wallis and Wilcoxon rank-sum tests, to identify differentially expressed genes. Hierarchical clustering was then performed using Cluster software on standardized data and expression maps of clustered genes were created using TreeView focussing specifically on the 114 angiogenesis-related genes. Upregulated genes are shown in red, whereas downregulated genes are shown in green.
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Intertumoral Heterogeneity of Angiogenesis-Related Genes in HNSCC To validate some of the microarray data and investigate the specific sources of the global angiogenic heterogeneity observed in HNSCC, we initially focused on IL-8/CXCL8, VEGF, FGF-2, and HGF for a number of reasons. First, these cytokines are known to play important roles in the induction of angiogenesis in HNSCC (reviewed in Lingen 26 and Hasina and Lingen 27 ). Secondly, the gene expression data from the HNSCC tumor samples suggested that there was a considerable amount of intertumoral variability in the production of message for these cytokines. In addition, each of the factors was elevated in one of the clusters, with VEGF and FGF-2 highly expressed in cluster A, and IL-8/CXCL8 and HGF highly expressed in cluster B. Validation of the initial microarray data was performed by determining the protein expression of these angiogenic factors in two different cohorts of HNSCC patients. First, immunohistochemistry was performed on frozen sections from the original 13 HNSCC samples that were used for the microarray studies. Because of the limited size of the original 13 frozen samples, immunohistochemical analysis was limited to VEGF and IL-8/ CXCL8. The immunohistochemical analysis demonstrated considerable variability in the protein expression levels of VEGF and IL-8/CXCL8 among these initial tumor samples ( Figure 4 , Table 2 ). Importantly, the IHC data correlated with the array data for VEGF and IL-8/CXCL8 (Figure 4) . To further validate the array findings, IHC was performed on additional formalin-fixed paraffin-embedded archival specimens assembled onto TMA that contained a histological diagnosis of normal (n ¼ 74), dysplasia (n ¼ 73), or HNSCC (n ¼ 223). For these TMAs, IHC was performed for VEGF, IL-8/CXCL8, HGF, and FGF-2. Normal oral mucosa rarely expressed VEGF (5%), IL-8/CXCL8 (2%), FGF-2 (0%), and HGF (0%). In addition, when present, the relative levels of expression in the normal oral mucosa were low compared to the dysplastic and malignant oral mucosal lesions ( Table 3) . The dysplastic oral mucosa had a higher incidence of expression as well as higher levels of VEGF (42%), IL-8/CXCL8 (23%), FGF-2 (15%), and HGF (11%) expression (Table 3) . Finally, the incidence of VEGF (72%), IL-8/CXCL8 (55%), FGF-2 (40%), and HGF (30%) protein expression as well as the intensity of expression was greatest in the HNSCC samples (Table 3 ). These data also validate the findings from the initial cohort of HNSCC samples and underscore the presence of heterogeneity of angiogenic factors secreted by HNSCC.
Angiogenesis Expression Profile and Therapeutic Outcome
In addition to raising mechanistic questions regarding the molecular differences underlying intertumoral variability of angiogenic phenotype between individual cases of HNSCC, these findings lead one to consider the potential clinical implications of this observation. Specifically, we hypothesized Angiogenic heterogeneity in head and neck cancer R Hasina et al that antiangiogenic therapies based upon the blockade/ neutralization of a specific angiogenic molecule, such as VEGF, would result in the lack of or a muted clinical response in certain subsets of patients because the target of therapy was not the predominant angiogenic factor produced by a particular neoplasm. We chose VEGF as our proof of principle molecule because therapies targeting VEGF have been approved by the FDA for certain malignancies and is under extensive investigation in a myriad of clinical trials for other anatomic sites. To test our hypothesis, we screened a number of HNSCC cell lines using ELISA to identify HNSCC cell lines that were either high or low producers of VEGF. Compared to normal keratinocytes, the OSCC-3 cell line was found to be the highest, whereas the SQ20-B and SCC-17B cell lines produced some of the lowest levels of VEGF protein (Figure 5a ). It was also known that these tumor cell lines were sufficiently capable of growing in nude mice. We, therefore, established tumor xenografts of OSCC-3, SQ20-B, and SCC-17 B cells in eight-week-old athymic nude mice to compare the ability of anti-VEGF antibodies to inhibit the growth of these tumors in vivo. Prior to the initiation of anti-VEGF therapy, tumors were allowed to grow to an average volume of 200 mm 3 after which the mice were randomized into three experimental groups (n ¼ 10 animals per treatment group) and treatment initiated. Group one was treated with 100 mg anti-human VEGF antibody, group two with a nonspecific human IgG control antibody, and group three with PBS. All treatments were administered intraperitoneally on days 0, 3, 6, and 9, and tumor volumes were measured until day 12. Treatment of mice with anti-VEGF antibodies markedly inhibited the growth of the OSCC-3 tumor xenografts (Figure 5b ), while treatment with either PBS or the nonspecific IgG did not alter tumor growth rates. At day 12, the mean tumor volumes from the VEGF-treated mice were , while tumor volumes for the PBS and IgG treated mice were 3287 ± 1202 and 3021 ± 1147 mm 3 , respectively. There was a statistically significant interaction between group and time (Po0.001). Comparisons between groups, at each time point separately, were then made using ANOVA. There was not a statistically significant difference between groups at day 0 (P ¼ 0.96). There was a significant difference between groups at day 3 (P ¼ 0.03) with even more significant differences at day 6 (P ¼ 0.001), day 9 (P ¼ 0.008), and day 12 (P ¼ 0.004). The observed differences were due to the differences in tumor volume between the VEGF vs PBS and the VEGF vs IgG groups. These data suggest that the inability of the OSCC-3 bearing mice treated with anti-VEGF to grow beyond a certain threshold in size was not due to a direct inhibition of tumor cell proliferation itself. Rather, it was likely due to the direct inhibition of tumor angiogenesis. Conversely, anti-VEGF treatment had limited effect on the growth of the SQ20-B xenografts compared to the PBS and IgG-treated mice (Figure 5c ). Tumor volumes from the VEGF-treated mice were 1195 ± 785 mm 3 , while tumor volumes for the PBS and IgG-treated mice were 1461 ± 551 and 1574 ± 821 mm 3 , respectively. There was a weak evidence for an interaction between group and time (P ¼ 0.07). Comparisons between groups, at each time point separately, were then made using ANOVA. There was no statistically significant difference between groups at day 0 (P ¼ 0.98), day 3 (P ¼ 0.50), day 6 (P ¼ 0.08), and day 9 (P ¼ 0.10) or day 12 (P ¼ 0.37). Similarly, anti-VEGF treatment demonstrated a modest effect on the growth of the SCC-17B xenografts compared to the PBS and IgG-treated mice on day 12 (Figure 5d ). Tumor volumes from the VEGF-treated mice were 238.5 ± 76.9 mm 3 , while tumor volumes for the PBS and IgG treated mice were 432.5 ± 219.5 and 548.6 ± 284.6 mm 3 , respectively. The interaction between group and time was not statistically significant (P ¼ 0.19). Additionally, the group main effect was also not significant (P ¼ 0.31). Thus, there was no evidence found for a difference in tumor volume change, or in tumor volume averaged over time, between groups. Since there was not a significant interaction or group main effect, comparisons between groups at each time point separately were not performed. However, the change in tumor volume from day 0 to day 12 was also examined and no statistically significant difference between groups based on this summary measure was found (P ¼ 0.07 from ANOVA).
To confirm our hypothesis that the inhibition of tumor growth was due to a direct effect of anti-VEGF therapy on the tumor microvasculature, we used the surrogate markers of MVD, proliferation, and apoptosis indices of the tumor samples. For the OSCC-3 xenografts (a high VEGF secreter), tumors from all three treatments (PBS, IgG, and anti-VEGF) had proliferation indices that were similar ( Figure 6 ). However, the tumor treated with anti-VEGF demonstrated a significantly higher apoptotic index when compared to either the PBS or the IgG-treated animals ( Figure 6 ). Similarly, while the PBS and IgG-treated animals demonstrated a robust MVD, the anti-VEGF-treated animals were more sparsely located in the xenograft. For the SQ-20B xenografts (a low VEGF secreter), tumors from all three treatments had high rates of tumor cell proliferation and MVD counts with low apoptotic indices ( Figure 6 ).
Taken together, these data underscore the need for a clearer understanding of angiogenic heterogeneity within HNSCC, particularly with the advent of targeted therapies. In addition, these data suggest that ongoing clinical trials may be observing less than optimal treatment outcomes and that these outcomes may be improved by prospectively determining if the molecular target of the therapy is produced at sufficient levels to warrant treatment with that specific therapy.
DISCUSSION
Like all solid tumors, HNSCC must develop direct and indirect mechanisms to induce the production of new blood vessels. Several dozen candidate angiogenic molecules are produced by keratinocytes and by HNSCC (reviewed in Lingen 26 and Hasina and Lingen 27 ). However, the majority of studies have only explored the expression of a single angiogenic factor in a cohort of HNSCC specimens or cell lines. To date, there are limited studies that have investigated the simultaneous expression of multiple angiogenic factors in HNSCC. 18, [28] [29] [30] Furthermore, these studies have been done with relatively small sample sizes of cell lines or patients samples. Therefore, our knowledge of the spectrum and variability of angiogenic factors in this neoplasm is quite Figure 6 In vivo effects of anti-VEGF therapy on proliferation, apoptosis, and MVD on HNSCC expressing different levels of VEGF. Tumor xenografts consisting of either OSCC-3 (a high VEGF-producing cell line) or SQ20-B (a low VEGF-producing cell line) were treated with either PBS, IgG, or anti-VEGF. Tumor tissue was subsequently harvested, fixed in 10% buffered formalin, and paraffin embedded. Immunohistochemistry for CD31, PCNA and caspase 3 were performed to determine MVD, proliferation index, and rate of apoptosis (n ¼ 10 animals per treatment group).
Angiogenic heterogeneity in head and neck cancer R Hasina et al limited, and this may have a profound impact on our understanding of the tumor biology as well as our ability to develop well-designed targeted therapies. In this study, we performed gene expression profiling experiments on LCM harvested keratinocytes from HNSCC tumor samples to obtain global signatures of angiogenesis-related genes. Here, we report the finding of variability in the expression of 114 angiogenesis-related genes in HNSCC. In particular, a considerable amount of intertumoral variation in the expression of VEGF, IL-8/CXCL8, FGF-2, and HGF, important angiogenic factors in HNSCC, was observed. Given the relatively large number of different angiogenic factors that have been reported to be expressed by HNSCC 26, 27 it was surprising that only four of these appeared to be the most commonly found to be overexpressed. Although this does not necessarily decrease the potential importance of other cytokines/growth factors in a given tumor, it does suggest that VEGF, IL-8, FGF-2, and HGF are critically important globally in the induction of HNSCC related angiogenesis. The changes observed in the gene expression profiling experiments involving the original tumor samples were subsequently validated by IHC in these samples as well as a larger cohort of 370 samples containing normal, dysplastic, and malignant keratinocytes. In addition, we demonstrated by PCA the presence of tumors with two potentially distinct molecular subtypes, suggesting that there may be two unique global mechanisms by which HNSCC induce angiogenesis. Furthermore, evaluation of the in vivo angiogenesis index of these two clusters using MVD analysis demonstrated that there was a correlation between the angiogenesis gene profile of the tumors and their ability to stimulate blood vessel growth. Specifically, cluster A, which expressed higher levels of VEGF and FGF-2, had a higher angiogenic index than cluster B, which expressed lower levels of VEGF and FGF-2 and relatively higher levels of alternative angiogenesis-related genes such as IL-8/CXCL8 and HGF. The coexpression of these cytokine groups may be related to common mechanisms regulating their expression in HNSCC. [31] [32] [33] [34] [35] An important question is whether the differences in the angiogenesis-related genes expressed and the subsequent differences in MVD between the two clusters correlates with the clinical course. Unfortunately, owing to the fact that these were unlinked cases, there was a lack of follow-up information and we were, therefore, unable to address this issue. However, these questions are currently being pursued in a new cohort of patients in a prospective fashion at this time.
Whether or not angiogenesis occurs in a particular tissue depends upon the balance between the relative amounts of molecules that induce and molecules that inhibit angiogenesis. 36 In normal tissues, blood vessels are usually quiescent and cells usually secrete low levels of inducers and high levels of inhibitors. As normal cells progress towards malignancy, they must develop the ability to induce angiogenesis. To achieve this switch, tumor cells usually increase the amount of inducers and decrease the amount of inhibitors they secrete. There is considerable interest in determining how cells, progressing from normal to tumorigenic, switch from being antiangiogenic to angiogenic. In some animal models a distinct switch to the angiogenic phenotype is seen. 37 In other cases, the cells developing into tumors sequentially become more angiogenic in a step-wise fashion. 38, 39 The exact mechanism regarding how this occurs in most neoplasms is still unclear. However, a growing body of evidence suggests that the activation of oncogenes as well as the inactivation of tumor suppressor genes play an important role in this phenotypic switch. For example, expression of VEGF can be stimulated by various oncogenic stimuli such as ras, v-src, c-fos, and c-jun. [40] [41] [42] [43] Similarly, IL-8/CXCL8 expression can be induced by Ets-1 and ras. 44, 45 Alternatively, inactivation of the p53, VHL, and RB2/p130 TSGs results in increased VEGF production, 41, 46, 47 while p53 and MEF (ELF4) have been shown to downregulate the expression of IL-8/CXCL8. 48, 49 At this time, we do not know which of these genetic alterations may play a role in the modulation of VEGF and IL-8/CXCL8 in HNSCC. Additional investigation is required to provide a mechanistic link between alterations of various oncogenes and TSGs important in HNSCC and the angiogenic heterogeneity that is observed in this neoplasm. It was surprising to note in this study that we did not appreciate a significant alteration in the expression of known inhibitors of angiogenesis when comparing expression profiles between normal and malignant oral keratinocytes. The reasons for this are unclear. However, we are currently pursuing possible mechanistic explanations for this observation.
The in vivo animal studies reported here suggest that the clinical response of a given targeted antiangiogenic therapy, such as VEGF, is largely dependent on the expression of the target by the tumor itself. Anti-VEGF treatment of HNSCC tumor xenografts secreting high levels of VEGF inhibited tumor growth, whereas anti-VEGF treatment had limited effect on the growth of xenograft tumors of HNSCC producing low levels of VEGF. Because the status of VEGF expression of the tumor cell lines used in these experiments was known prior to treatment, one may argue that the outcome of this treatment was predictable and we would agree. However, the key point to be made is that ongoing antiangiogenic clinical trials typically do not include patient inclusion/exclusion criteria that require the prospective determination of whether or not a specific tumor is producing the angiogenic factor that is the target of the intended therapy.
In conclusion, our findings support the concept of intertumoral angiogenic heterogeneity. They imply that individual tumors within the same histological type can employ multiple mechanisms to induce angiogenesis. Moreover, they demonstrate the need for a more in depth understanding of the variability of the angiogenic phenotype within a given type of neoplasm as we begin to design targeted therapies aimed at blocking this critical phenotype. In addition, these data support the concept that one potential reason that antiangiogenesis clinical trials, in which a specific angiogenic factor is targeted, may have lower than expected clinical response rates due to the fact that therapy may have been used on certain tumors that do not produce the targeted factor. Finally, these data support the need for studies that explore the correlation between target expression and clinical outcome to a given therapy in conjunction with ongoing clinical trials.
